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Strengths and limitations of this study
 ► An important observational study aimed towards 
the understanding of the complex pathophysiolo-
gy of heart failure with preserved ejection fraction 
(HFpEF).
 ► Will provide insight whether the HFpEF syndrome 
is associated with increased arterial stiffness, as a 
result of increasing comorbidities on top of ageing.
 ► Comprehensive study of patients with increasing 
comorbidities investigating macrovascular/micro-
vascular function, echocardiographic/biochemical 
aspects and endothelial function in age, sex and 
body mass index- matched groups.
 ► A limitation of the study is that groups with more 
combinedcomorbidities (eg, diabetes mellitus, hy-
pertension and chronic kidney disease) should 
have been included to fully investigate the poten-
tial effect of increasing comorbidities on arterial 
stiffness, which might then lead to HFpEF. Further, 
the cross- sectional design of the study has related 
disadvantages.
AbStrACt
Aims There has been a paradigm shift proposing 
that comorbidities are a major contributor towards the 
heart failure with preserved ejection fraction (HFpEF) 
syndrome. Furthermore, HFpEF patients have abnormal 
macrovascular and microvascular function, which may 
significantly contribute towards altered ventricular- 
vascular coupling in these patients. The IDENTIFY- HF 
study will investigate whether gradually increased arterial 
stiffness (in addition to ageing) as a result of increasing 
common comorbidities, such as hypertension and 
diabetes, is associated with HFpEF.
Methods and analysis In our observational study, arterial 
compliance and microvascular function will be assessed 
in five groups (Groups A to E) of age, sex and body mass 
index matched subjects (age ≥70 years in all groups):
Group A; normal healthy volunteers without major 
comorbidities such as hypertension and diabetes mellitus 
(control). Group B; patients with hypertension without 
diabetes mellitus or heart failure (HF). Group C; patients 
with hypertension and diabetes mellitus without HF. Group 
D; patients with HFpEF. Group E; patients with heart failure 
and reduced ejection fraction (parallel group). Vascular 
function and arterial compliance will be assessed using 
pulse wave velocity, as the primary outcome measure. 
Further outcome measures include cutaneous laser 
Doppler flowmetry as a measure of endothelial function, 
transthoracic echocardiography and exercise tolerance 
measures. Biomarkers include NT- proBNP, high- sensitivity 
troponin T, as well as serum galectin-3 as a marker of 
fibrosis.
Ethics and dissemination The study was approved 
by the regional research ethics committee (REC), West 
Midland and Black Country 17/WM/0039, UK, and 
permission to conduct the study in the hospital was also 
obtained from the RDI, UHCW NHS Trust. The results will be 
published in peer- reviewed journals and presented in local, 
national and international medical society meetings.
trial registration number NCT03186833
IntroduCtIon
Heart failure (HF) is a major growing public 
health concern with approximately 20 million 
patients affected globally, posing a significant 
health economic burden, with an estimated 
cost of $108 billion per year worldwide.1 
In the UK alone, approximately 5% of all 
emergency medical admissions are due to 
heart failure with an approximate cost to the 
National Health Service of £1.9 billion per 
year.2 Heart failure with preserved ejection 
fraction (HFpEF) is reported to comprise 
about 50% of the total heart failure burden 
and continues to have a high and unchanged 
 o
n
 January 15, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027984 on 19 November 2019. Downloaded from 
2 Ali D, et al. BMJ Open 2019;9:e027984. doi:10.1136/bmjopen-2018-027984
Open access 
Figure 1 Overview of the hypothesis behind the IDENTIFY- 
HF study.
mortality over many years, a poor quality of life and 
similar readmission rates to heart failure and reduced 
ejectionfraction (HFrEF).3 4 The prognosis of HFpEF is 
comparable to systolic heart failure, now referred to as 
HFrEF, with an estimated 5- year mortality of around 50%. 
This is worrying as no treatments that influence outcome 
in HFpEF have so far been found.5 Most large- scale phar-
macological phase III clinical trials have been unsuc-
cessful.6 7 While there is no single reason contributing to 
the negative result of these trials, the most likely expla-
nation is that our understanding of the pathophysiology 
of the HFpEF syndrome remains incomplete and we are, 
therefore, currently unable to produce therapies targeted 
at the underlying mechanisms causing the syndrome.8 
Therefore, in order to develop evidence- based treatments 
in patients with HFpEF, the underlying diverse patho-
physiology requires further investigation.
Recently, there has been a shift in paradigm whereby 
comorbidities are thought to contribute significantly 
to HFpEF syndrome.9 Furthermore, current evidence 
strongly suggests that HFpEF patients have abnormal 
macrovascular and microvascular function with abnormal 
ventricular- vascular coupling.10 However, the effect 
of comorbidities on arterial stiffness and the HFpEF 
syndrome remains incompletely understood.
This study aims to investigate the pathophysiological 
process of HFpEF and this understanding will promote 
further research, aiding the development of new evidence- 
based interventions and/or early prevention strategies.
Hypothesis
HFpEF is a complex syndrome which is characterised by 
signs and symptoms of heart failure and a normal or a close 
to normal ejection fraction, evidence of left ventricular 
diastolic dysfunction, structural heart disease, altered left 
ventricular (LV) filling and raised brain natriuretic peptide 
(BNP).11 The complete pathophysiology is not known, 
however it is widely accepted that it is associated with 
cardiac and non- cardiac comorbidities.12 Cardiac abnor-
malities include altered atrial function, subtle alterations in 
LV systolic function and/or chronotropic incompetence.13 
Non- cardiac comorbidities, for example hypertension, 
diabetes mellitus, anaemia, pulmonary or renal diseases and 
obesity may contribute to the HFpEF syndrome. In terms 
of pathophysiology, diastolic dysfunction is a prominent 
feature of HFpEF patients to which many factors contribute 
including both myocardial and vascular stiffening.14
HFpEF patients are known to have altered vascular func-
tion. Balmain et al investigated the comparison in arterial 
compliance, venous capacitance and microvascular vasodi-
lator function in three patients’ groups with HFpEF, HFrEF 
and normal volunteers (non- HF). All the groups had coro-
nary artery disease.15 They found that there was reduced 
vascular compliance (increased arterial stiffness, decreased 
venous capacitance) in the HFpEF group compared with the 
HFrEF and non- HF groups. More recently, macrovascular 
and microvascular function was compared between HFpEF 
and hypertensive patients.10 This study found that there was 
decreased microvascular function with increase in arterial 
stiffness and depressed endothelial function in the forearm 
vasculature in the HFpEF group compared the hyperten-
sive group. These studies highlight the fact that abnormal 
vasculature is present and may be an important contributor 
to the HFpEF syndrome. Although the groups in the above- 
mentioned studies were matched for age and sex, what 
remains unclear is why certain patients of the same age and 
sex suffer from HFpEF while others do not. There is good 
evidence that hypertension,16 diabetes mellitus17 and chronic 
kidney disease18 all increase vascular resistance on their own. 
Ageing itself is known to be an independent risk factor for 
arterial stiffness and increase in pulse wave velocity.19 20 It is 
therefore reasonable to consider that HFpEF may not be 
due to a primary cardiac pathology but rather an end- result 
of non- cardiac comorbidities affecting vascular function and 
resistance with perhaps some secondary cardiac involvement. 
We hypothesised therefore, that arterial stiffness increases 
with comorbidities, on top of effects of normal ageing (as 
illustrated in figure 1), contributing towards the HFpEF 
syndrome. It is possible that a gradual increase in arterial 
stiffness may be causing early fatigue of the cardiac muscles 
(as it struggles to pump into an ever- increasing high- pressure 
vascular circuit) resulting in elevation of left ventricular end 
diastolic pressure and subsequently HFpEF.21
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Figure 2 Study flow chart. CPEX,cardiopulmonary exercise 
test; FBC, full blood count; HbA1c, glycated haemoglobin; 
hs- cTnT, high- sensitive cardiac troponin T; LFT, liver 
function test; PWV, pulse wave velocity; TTE, transthoracic 
echocardiography; U&E, urea and electrolytes; 6- MWT,6 min 
walk test.
MEtHodS
Study design
Single- centre, observational study in five age, sex and 
body mass index (BMI) matched groups varying on the 
presence or absence of diabetes, hypertension or heart 
failure.
definitions
Heart failure in our study is defined as: (a) relevant symp-
toms/signs/radiographic findings as indicated by Boston 
criteria22 and (b) need for diuretic therapy. Preserved 
LV systolic function is defined as a LV ejection frac-
tion (LVEF) of >50%, measured by echocardiography. 
Impaired LV systolic function will be defined as a LVEF 
of <40% in accordance with the European Society of 
Cardiology (ESC) guidelines on heart failure. LVEF will 
be calculated using semi- quantitative assessment with 16 
segment wall motion scoring.23 HFpEF, is defined as signs 
and symptoms of HF with LVEF >50% and raised natri-
uretic peptides (BNP >35 pg/mL or NT- proBNP >125 pg/
mL) along with one other criteria: (i) structural heart 
disease (left atrial enlargement or left ventricular hyper-
trophy) on transthoracicechocardiography (TTE), (ii) 
evidence of LV diastolic dysfunction based on ESC guide-
lines 2016 or iii) hospitalisation with heart failure within 
12 months prior to study entry.
Hypertension is defined in this study as a documented 
resting clinic systolic blood pressure >140 mm Hg or 
diastolic blood pressure >90 mm Hg. Diabetes mellitus 
will be defined according to the WHO criteria.24
Study setting
The study will be conducted at two sites: the cardiology 
research department at University Hospitals Coventry 
& Warwickshire (UHCW) NHS Trust and at the cardiac 
rehabilitation facility of the hospital (Atrium Health). The 
study assessments are expected to be undertaken during 
a single visit, however a second visit will be arranged if all 
the assessments are not completed.
Study population
Patients will be matched according to age, gender, BMI 
and allocated to five different groups. All patients will be 
aged 70 years or above.
The first four groups will constitute: Group A, normal 
healthy volunteers without major comorbidities including 
hypertension and diabetes; Group B, patients with hyper-
tension without diabetes mellitus; Group C, patients with 
hypertension and diabetes mellitus and Group D, patients 
with HFpEF. The fifth, parallel Group E will comprise the 
HFrEF group. In order to make meaningful comparison 
between the groups 21 patients each are planned to be 
recruited in groups A to D and 11 in group E determined 
by sample size calculation.
Aims
We plan to assess vascular function, and cardiovascular 
performance in different cohorts (figure 2). Arterial 
resistance measured by pulse wave velocity (PWV) will 
be the primary outcome measure and will be compared 
between Groups A to D. A separate comparison will be 
made between Groups D and E. We intend to investi-
gate if there is increased arterial resistance from Group 
‘A’ to Group ‘D’ and if there is a significant difference 
in arterial resistance between Groups ‘D’ and ‘E’. The 
secondary measures will focus on endothelial function 
(Laser Doppler measurements) and other cardiovascular 
performance measures; peak oxygen uptake (VO2) by 
cardiopulmonary exercise test (CPEX), and 6 min walk 
distance. Bloods samples will be taken for NT- proBNP, 
high sensitivity troponin T and serum will be stored for 
testing later for vascular biomarkers and galectin-3.
Inclusion criteria
 ► Group A: healthy males or females aged ≥70 years 
without major systemic illnesses including hyperten-
sion and diabetes mellitus.
 ► Group B: males or females aged ≥70 years with hyper-
tension only.
 ► Group C: males or females aged ≥70 years with hyper-
tension and diabetes mellitus but without HF.
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 ► Group D: males or females aged >70 years with HFpEF.
 ► Group E: males or females aged ≥70 years with HFrEF.
Exclusion criteria
 ► Acute coronary syndrome (including myocardial 
infarction (MI)), cardiac surgery, other major cardi-
ovascular surgery within 3 months or urgent percuta-
neous coronary intervention within 30 days of entry.
 ► Patients who have had an MI, coronary artery bypass 
graft or other event within the 6 months prior to entry 
unless an echo measurement performed after the 
event confirms a LVEF ≥50%.
 ► Current acute decompensated HF requiring intrave-
nous therapy.
 ► Alternative reason for shortness of breath such as: 
significant pulmonary disease or severe chronic 
obstructive pulmonary disease, haemoglobin (Hb) 
<10 g/dL or BMI >40 kg/m2.
 ► Severe left- sided valvular heart disease.
 ► Hypotension (systolic blood pressure <100 mm Hg).
 ► Severe liver failure.
 ► Primary pulmonary hypertension.
 ► Bedbound/immobile patients.
 ► Chronic renal failure with creatinine of >250 μmol/l.
 ► Significant peripheral vascular disease (PVD), defined 
as having signs of absent peripheral pulses or reported 
claudication pain or documented history of PVD.
Sample size calculation and statistical analysis
The sample size calculation is based on estimates obtained 
in studies reported by Balmain et al15 and Maréchaux 
et al.10 The aim is to detect a difference in the primary 
outcome; PWV, between the five groups of patients 
recruited to the study with the significance level being set 
at 5% if the p value is less than 0.05. The estimates range 
from a mean PWV of 8.6 m/s for the control group to 
11.3 m/s for the HFpEF group and the within group SD is 
assumed to be SD=1.7 m/s and equal for each group. No 
estimate of the mean PWV was available in the literature 
for the hypertension and diabetes mellitus group, so this 
value was assumed to be in exactly in the middle of the 
hypertension and HFpEF mean. A sample size of n=11 for 
HFrEF patients and n=21 for all other groups will allow 
to detect a difference in PWV between the five groups for 
the aforementioned configuration of means and SD with 
80% power using the overall F- test in a one- way analysis 
of variance. The study would additionally be sufficiently 
powered for the pair- wise comparison of the control group 
with the hypertension group and the control group with 
the HFpEF group. Statistical analysis will be performed 
with IBM SPSS Statistics for Windows, V.22.0. Descriptive 
statistics will be given as number (percentage), as average 
(±SD) or median (IQR).
Study procedures
Participants will attend our Research Unit in the morning. 
To avoid confounding factors for vascular measurements, 
participants and will be asked to abstain from caffeine and 
tobacco for 12 hours, and to omit their morning blood 
pressure medication. Vascular function studies will be 
carried out in a quiet, temperature- controlled (21°C to 
23°C) room with subjects in the supine position, following 
at least 10 min of rest. Arterial compliance will be assessed 
using applanation tonometry to measure aortic PWV. 
Cutaneous microvascular function will be assessed by 
Laser Doppler flowmetry, after which the blood test and 
TTE measurements will be performed. Subsequently, 
patients will be asked to undertake the 6- MWT and CPEX 
test (figure 2).
Screening and recruitment
Group A: Participants will be recruited via the UHCW 
Hospital Radio, senior citizen’s group in the community 
and via friends and relatives of colleagues. These patients 
will receive an invitation letter and participant informa-
tion sheet to read, they will then be contacted by the study 
coordinator at least 24 hours after receiving the invitation 
letter to answer any questions. If the participant is inter-
ested in taking part in the study, they will be invited for a 
screening visit at UHCW to confirm their eligibility. This 
will involve a full medical history, physical examination, 
blood pressure measurement and blood tests (fullblood 
count, glucose, glycatedhaemoglobin and renal func-
tion). If the eligibility criteria are met, the study appoint-
ment will be organised.
Group B and C: Patients will be approached and screened 
for eligibility at the hypertension and diabetes outpatient 
clinics at UHCW. Eligible participants will receive an 
invitation letter and participant information sheet. They 
will then be contacted by the study coordinator at least 
24 hours later to answer any questions, and to organise a 
study appointment .
Group D and E: Patients will be approached and 
screened for the eligibility criteria at the HF commu-
nity clinic. Eligible participants will receive an invita-
tion letter and participant information sheet. They will 
then be contacted by the study coordinator after at least 
24 hours to answer any questions, and to organise a study 
appointment.
Study assessments
Participants in all groups will have the same assessments 
as follows (table 1):
Heart rate and one brachial blood pressure measurement will 
be recorded over a 30 s time period. These measure-
ments will be performed three times for each subject and 
averaged.
Blood tests will include full blood count, renal function 
and electrolytes, liver function tests, NT- proBNP and 
high- sensitive cardiac troponin T. Blood samples will be 
frozen in the Tissue Bank at UHCW for further tests such 
as vascular and other biomarkers for example, galectin-3 
to be performed at a later date.
Urinalysis will be performed from a mid- stream urine 
sample obtained for albumin and creatinine levels. This 
will further be stored at the Tissue Bank UHCW to be 
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Table 1 Schedule of measures for every participant within the study
Group A only: Separate screening visit prior to the study visit to check that the participants meet the eligibility 
criteria; full medical history, physical examination, blood pressure and blood tests (full blood count, Glucose, glycated 
haemoglobin and renal function)
Time of day Procedures/assessments*
Morning Eligibility check
Informed consent
Demographic data (date of birth, sex, ethnicity, height and weight)
Relevant clinical history
Current medications
Blood pressure and heart rate
Pulse wave velocity to measure arterial resistance
Laser Doppler to measure microvascular function
Blood tests: full blood count, renal function and electrolytes, liver function tests, NT- proBNP, high- 
sensitive cardiac troponin T. Samples will be frozen and stored for future analysis of vascular and other 
biomarkers, for example, galectin-3.
Urine test: albumin and creatinine. samples will be frozen and stored for future analysis of metabolite 
profiles.
Lunch
Afternoon Transthoracic echocardiography: tissue Doppler imaging and strain rate imaging
6 min walk test
Cardiopulmonary exercise test
All assessments will be aimed to be completed in a single visit. However, a possible second visit may be arranged either at Atrium Health or 
University Hospitals Coventry and Warwickshire NHS Trust for completion of all assessments, if required.
analysed at a later date for metabolite profiles (‘metab-
olomics’), related to cardiovascular risk and insulin 
resistance.
TTE will include measurements of cardiac chamber 
sizes, ventricular function including LVEF, indices of LV 
diastolic function, assessment of valvular heart disease, 
tissue Doppler imaging and strain rate imaging. Further-
more, right ventricular structure and function and pulmo-
nary artery pressures will be assessed.
Exercise tolerance will be assessed by a 6 min walk test and 
a cardiopulmonary exercise test (CPEX) in each patient. 
The CPEX test will involve measurement of the oxygen 
consumption and carbon dioxide production and heart 
rate and blood pressure monitoring while exercising on 
an exercise bike. Further details are provided below.
Pulse wave velocity protocol
Arterial resistance will be assessed using pulse wave 
velocity. Aortic PWV will be evaluated using a high- fidelity 
micromanometer (SPC-301; Millar Instruments, Texas, 
USA) coupled with the SphygmoCor system (Sphyg-
moCor BPAS; PWV Medical, Sydney, Australia). A hand- 
held micromanometer- tipped probe will be applied to 
the skin overlying the radial, femoral and carotid arteries 
at the point of maximal arterial pulsation. Gated to a 
simultaneous ECG, the pulse wave will be recorded at 
each point. This data, in combination with the measured 
body surface distance between the two points, will be 
incorporated by the software programme to calculate 
PWV in metres per second (m/s). The measurements will 
be repeated three times and the average PWV will be used 
for analysis.
Laser doppler flowmetry protocol
The forearm cutaneous blood flow will be measured at rest 
and during reactive hyperaemia by using Laser Doppler 
flowmetry (LDF), in accordance to the Fizeau- Doppler 
principle.25 Measurements of cutaneous blood flow will 
be expressed in perfusion units and the Laser Doppler 
signal will be continuously monitored on a computer 
(Moor instruments, VMS software V.4.06) coupled with 
Moor instruments system (moorVMS- VASC). The thenar 
eminence will be used for the placement of the LDF probe 
(VP1T/7), consistently at the same place, before and post 
the occlusive reactive hyperaemia manoeuvre. The room 
temperature will be maintained at 22°C during forearm 
cutaneous blood flow measurements. The reactive hyper-
aemia will be produced by occluding the forearm blood 
flow with a pneumatic cuff inflated to a pressure of 50 mm 
Hg above the SBP for 3 min. The signal obtained during 
complete arterial occlusion will be taken as the biological 
zero for cutaneous blood flow measurements before and 
during reactive hyperaemia. Resting flow will be taken as 
the average of a 6 min stable LDF recording. The defi-
nition of the measurements taken are shown in figure 3 
and the power spectral density will be measured using the 
basic fast Fourier transform algorithm10
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Figure 3 Laser Doppler flowmetry for assessment of 
endothelial function. Schematic representation of flow 
(perfusion units) as a function of time in rest, after arterial 
occlusion and after cuff release. (adapted with permission of 
Moor diagnostics).
Cardiopulmonary exercise test & 6 minute walk test
Exercise tolerance will be assessed by 6 min walk test and 
CPEX, conducted in accordance with existing guide-
lines.26 27 For the walk test, participants will walk as far 
as possible in 6 min along a flat, obstacle free corridor, 
turning 180 degrees every 30 m. For CPEX, partici-
pants will pedal a cycle ergometer at 70 rpm until voli-
tional fatigue, using a ramp protocol. Breath- by- breath 
measurement of oxygen (O2) consumption, 2carbon 
dioxide production and ventilation will be used to deter-
mine key cardiorespiratory parameters including peak O2 
uptake2, VO2 at the anaerobic threshold2 and ventilatory 
efficiency.2 Blood pressure, ECG and O2 saturation will 
be continuously monitored. Criteria for a peak test will 
include respiratory exchange ratio >1.10.28
blinding
In order to reduce observer- bias the operator involved 
in the assessments of the primary outcome (pulse wave 
velocity) will be blinded to the comorbidities of the group 
of patients (A to E).
Primary outcome
Our primary outcome will be a difference in arterial 
resistance between each of the five groups, as measured 
by aortic PWV. In addition, specific comparisons will be 
made between the control and hypertension groups as 
well as the control and HFpEF groups.
Secondary outcomes
The secondary outcomes are to assess and compare endo-
thelial function and cardiovascular performance in all 
groups as measured by the following:
 ► Blood tests: NTproBNP, high sensitivity troponin T, 
galectin-3.
 ► Urinalysis: Albumin, Creatinine and metabolite 
profiles (‘metabolomics’), related to cardiovascular 
risk and insulin resistance.
 ► Transthoracic echocardiography: Indices of LV dias-
tolic function, tissue Doppler imaging, strain rate 
imaging and measuring flow with pulsed- wave Doppler 
echocardiography interrogating the LV outflow tract.
 ► Exercise tolerance: 6 min walk test and a CPEX.
End of study definition
The study will be closed at the last patient’s study visit.
Study funding and sponsor
The study has been funded by a research grant from the 
West Midlands Clinical Research Network, National Insti-
tute of Health Research, UK. The study is sponsored by 
the Research, Development & Innovation department of 
the University Hospitals Coventry & Warwickshire NHS 
Trust (RDI, UHCW), UK.
Study oversight
The study will be monitored and overseen by the Study 
Management Group and the Research, Development and 
Innovation Department at UHCW.
Ethical approval and research governance
The study will be conducted in compliance with the princi-
ples of the Good Clinical Practice guidelines and in accor-
dance with all applicable regulatory guidance, including, 
but not limited to, the Research Governance Framework 
and the Health Research Authority, UK. Progress reports 
and a final report at the conclusion of the study will be 
submitted to the approving research ethics committee 
within the timelines defined by the committee.
Patient and public involvement
Patient involvement has been crucial to the design of 
and protocol of the study. Detailed advice was obtained 
from patient and public involvement (PPI) representa-
tives, which led to the tests being allowed to be done over 
two visits after screening. The non- invasive nature of the 
investigations was particularly favoured by the PPI group. 
Furthermore, optional transport was provided to partic-
ipants following their recommendation. Patients seen 
in the relevant outpatient department will be invited to 
participate in the study. Ongoing PPI input is confirmed 
during the study steering committee meetings. The 
results of the study will be
disseminated to all the participants via post.
dissemination and impact
The hypothesis on which this study is based has been 
published.10 The results of the study will be presented at 
national and international conferences and released in 
appropriate media outlets, including social media. The 
results are expected to be published in peer- reviewed 
journals and presented in local, national and interna-
tional medical scientific congresses and meetings. The 
study is anticipated to shed light on whether vascular 
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stiffness is an important determinant of HFpEF which in 
turn could potentially encourage research for new thera-
peutic targets.
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